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A variant form of the heptacosapeptide amide secretin, with C-terminal -Val-Gly-Lys-Arg instead of valine 
amide, has been isolated from porcine upper intestinal tissue. Unexpectedly, this triacontapeptide exhibited 
a substantially higher bioactivity than the heptacosapeptide amide. 
Secretin Secretin precursor Amino acid sequence Secretin bioactivity Porcine intestinal extract 
1. INTRODUCTION 
Secretin is a hormone stimulating pancreatic 
secretion [l]. It was first isolated from the upper 
part of porcine intestine [2] and subsequently also 
from chicken, bovine and human intestine [3-51. 
In all these cases it was found to be a polypeptide 
of 27 amino acid residues. The porcine and bovine 
secretins are identical. They differ from the human 
form in two positions and the chicken form in 13 
positions. Bioactive and immunoreactive secretin 
material has also been found in brain extracts 
[4,71. 
The C-terminal amino acid residue of secretin 
(valine in porcine/bovine/human, methionine in 
chicken) is, as in many other hormonally active 
peptides, amidated. However, a variant form of 
secretin which is not amidated at its C-terminal 
residue but instead has a C-terminal residue of 
glycine has been described [8]. This extended form 
of secretin is biologically active in a bioassay for 
secretin, but its potency has not been determined. 
It is known that in the precursors of amidated pep- 
tides, the amino acid that becomes amidated in the 
mature hormone is always followed by a glycine 
residue and it is the amino group of this glycine 
residue that gives rise to the C-terminal amide 
group in the enzymatic amidation reaction [9]. The 
glycine is, in turn, usually followed by a pair of 
basic amino acid residues. 
We now report on the isolation of a secretin 
variant, 30 amino acid residues long, which is a 
secretin molecule extended with a glycine followed 
by a lysine and an arginine at its C-terminus. This 
secretin variant is at least as potent as secretin in 
stimulating the secretion of bicarbonate by the 
pancreas in the anesthetized cat [lo]. 
2. MATERIALS AND METHODS 
2.1. Preparation of the starting material 
A fraction, earlier described as the starting 
material for the purification of VIP [I 11, was fur- 
ther purified by, two CM-cellulose chromatog- 
raphies. The first one was carried out in a 0.02 M 
phosphate buffer at pH 6.4 with a salt gradient of 
O-O.3 M NaCI. The fraction, eluting at about 
0.15 M NaCl, was further chromatographed on a 
second CM-cellulose column, eluted by stepwise 
increase of NHdHCO3 concentration (0.02, 0.04, 
0.2 M). The fraction which is here referred to as 
the starting material for the purification of the 
secretin variant was eluted with 0.04 M NH4HC03. 
Details concerning the two CM-cellulose chroma- 
tographies will be described elsewhere. 
2.2. High-performance liquid chromatography 
(HPLC) 
Reverse-phase HPLC was carried out on a 
Waters PBondapak C,s column (7.8 x 300 mm, 
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10 Frn particle size) or an LKB Ultropac TSK 
ODS-120T column (4.6 x 250 mm, 5 pm particle 
size) with 0.12% trifluoroacetic acid (TFA) in 
water (solvent A) and 0.1% TFA in acetonitrile 
(solvent B), Ion-exchange chromatography was 
performed on an LKB Ultropac TSK 535 CM- 
column (7.5 x 150 mm) with 0.02 M sodium 
phosphate buffer at pH 6.4 and a gradient of NaCl 
(O-O.3 M). Both types of separations were carried 
out on an instrument from Waters Associates. 
2.3. Bioassay 
The biological activity was measured by the 
ability of the material to stimulate the secretion of 
alkali in the pancreatic juice of anesthetized cat 
[lo]. The sample was compared to a secretin stan- 
dard (3500 clinical units per mg). 
2.4. Proteolytic fragmentation 
The peptide was digested with T&X-treated 
trypsin (Worthington) for 6 h or TLCK-treated 
chymotrypsin (Merck) for 4 h in 1% NHeHCOs at 
room temperature. The ratio of peptide to enzyme 
Table 1 
Preparation of starting material 
The upper part of porcine intestine was boiled, frozen 
and minced. 
Extraction with 0.5 M acetic acid. Peptides adsorbed on 
alginic acid. Elution with 0.2 M HCI and precipitation 
with NaCi. 
Gel filtration on Sephadex G-25 (fine) in 0.2 M acetic 
acid. 
Extraction with methanol. Soluble material precipitated 
with ether. 
Gel filtration on Sephadex G-25 (fine) in 0.2 M acetic 
acid. 
Ion-exchange chromatography on CM-cellulose. Elution 
with 12.5 mM phosphate buffer, pH 8. 
Ion-exchange chromatography on CM-cellulose in 
0.02 M sodium phosphate buffer, pH 6.4. Elution 
with a gradient of NaCl (O-O.3 M). 
Ion-exchange chromatography on CM-cellulose with a 
stepwise increase of NI&HC03 concentration (0.02, 
0.04, 0.2 M). The ‘starting material’ was eluted with 
0.04 M NHaHCO3. 
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was 50: 1 by wt. The digests were separated by 
reverse-phase HPLC on a PBondapak Cig column 
as described above. The gradients used were, for 
tryptic fragments, O-40% solvent B for 40 min at 
a flow rate of 1 ml/min and, for chymotryptic 
fragments, lo-25% solvent B for 30 min at 
1 ml/min. 
2.5. Amino acid corn~~~it~o~ analysis 
Hydrolysis was carried out at 110°C for 24 h in 
evacuated tubes with 6 M HCl containing 0.1% @- 
mercaptoethanol. The tryptic digest hydrolysates 
were analyzed in a Waters amino acid analysis 
system using precolumn derivatization with o- 
phthalaldehyde [12], All other hydrolysates were 
analyzed in a Beckman 121 amino acid analyzer. 
2.6. Identification of free arginine 
The tryptic digest was treated with PITC [13] to 
form the phenylthiocarbamyl derivatives of the 
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Fig. 1. Purification of the starting material by reverse- 
phase HPLC. Sample: about 1.8 mg/run of the fraction 
defined as the starting material in section 2. Column: 
Waters yBondapak Cts (7.8 x 300 mm, 10pm particle 
size). Mobile phases: A, 0.12% trifluoroacetic acid 
(TFA)/water; B, 0.1% TFA/acetonitrile. Flow rate: 
2 ml/min. Gradient: 32-38% B, 30 min, indicated by 
the dotted line. The secretin bioactivity is indicated by 
the bar. 
Volume 184, number 2 FEBS LETTERS May 1985 
fragments. These were separated by HPLC on a 
Spherisorb ODS 2 column (4.6 x 100 mm, 3 pm 
particle size) using a system described in [ 141 but at 
pH 6.0. In this system, free amino acids were iden- 
tified as PTC-derivatives. 
3. RESULTS AND DISCUSSION 
During the purification of variant forms of VIP 
[ 151 a certain fraction was observed to have a 
secretin- rather than a VIP-like bioactivity. Since 
this active fraction originated from material 
eluting later than secretin on a CM-cellulose 
chromatography, the activity could be assumed to 
be due to a peptide with a more alkaline isoelectric 
point than that of secretin, rather than to secretin 
itself. It was therefore of interest to isolate this 
material, and to characterize it. 
A schematic presentation of how the starting 
material was obtained is shown in table 1. The 
final purification of the secretin variant from the 
___--- 
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Fig.2. Final purification of secretin-Gly-Lys-Arg by 
reverse-phase HPLC. Sample: 65 pg of the bioactive 
fraction from the CM-HPLC step. Column: LKB 
Ultropact TSK ODS-120T (4.6 x 250 mm, 5 pm particle 
size). A and B as in legend to fig. 1. Flow rate: 1 ml/min. 
Gradient: 2540% B, indicated by the dotted line. The 
larger peak corresponds to the secretin variant. 
starting material was obtained by 3 HPLC steps. 
The first step was a reverse-phase chromatography 
on a PBondapak Cis column using a linear gra- 
dient, described in the legend to fig.1. The active 
fraction was further subjected to an ion-exchange 
step on a TSK-CM column eluted with a gradient 
of 0.12-0.3 M NaCl in 0.02 M phosphate buffer, 
pH 6.4, for 15 min and isocratic elution at 0.3 M 
NaCl in the same buffer for another 15 min. The 
flow rate was 1 ml/min. Finally the material was 
desalted by reverse-phase HPLC in the system 
described in the legend to fig.2. This step also gave 
some purification (fig.2) and the isolated peptide 
was considered pure after this step. Active frac- 
tions were identified with the bioassay for secretin 
(described in section 2) throughout the purification 
procedure. 
The amino acid composition of the intact pep- 
tide is shown in table 2. Comparison of this amino 
acid composition to that of secretin indicates that 
the isolated peptide differs from porcine secretin in 
containing a Lys residue and one additional 
residue each of Arg and Gly. To ascertain whether 
the purified peptide is a variant form of secretin, 
tryptic digestion was carried out and the fragments 
obtained were separated by reverse-phase HPLC. 
Table 2 
Amino acid composition of the secretin variant 
Amino acid 
LYS 
His 
Arg 
Asx 
Thr 
Ser 
GlX 
GlY 
Ala 
Val 
Leu 
Phe 
Secretin .variant Secretin 
1.1 (1) - 
1.3 (1) 1 
4.9 (5) 4 
2.1 (2) 2 
1.8 (2) 2 
3.3 (4) 4 
3.0 (3) 3 
3.0 (3) 2 
1.2 (1) 1 
1.0 (1) 1 
6.0 (6) 6 
1.0 (1) 1 
Total 30 27 
Values are molar ratios without correction for 
destruction, incomplete hydrolysis or impurity. Figures 
within parentheses represent the predicted number of 
each amino acid in the secretin variant 
349 
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The chromatogr~s of the tryptic fragments of the 
purified peptide and of secretin are shown in figs 
3 and 4, respectively. Only one fragment eluted at 
different positions. This fragment corresponds to 
the C-terminal fragment TS as shown by the amino 
acid composition. Each tryptic peptide of the 
isolated peptide was hydrolyzed and subjected to 
amino acid analysis. The amino acid compositions 
of the tryptic fragments are shown in table 3. The 
C-terminal fragment of the isolated peptide, Ts, 
contains an additional Gly and a Lys residue as 
compared to the corresponding Ts fragment of 
secretin, while the other fragments (Ti-T4) are 
identical with the secretin fragments. Chymotryp- 
tic degradation of secretin and of the isolated pep- 
tide was carried out in parallel and led in both 
cases to numerous fragments. With one exception 
each fragment of the peptide appeared to be iden- 
tical to a fragment of secretin and vice versa. The 
amino acid compositions of the two nonidentical 
fragments were determined (table 3). That of the 
secretin fragment was Glyl, Glxr , Leui, Vail, une- 
quivocally showing that it represented the C- 
terminal Gin-Gly-Leu-V~-N~2 sequence of 
secretin. That of the variant fragment was Argr , 
1 
Fig.3. Separation of the tryptic fragments of the secretin 
variant by reverse-phase HPLC. Sample: about 4pg 
trypsin-degraded secretin variant. Column: the column 
described in legend to fig.%. Mobile phases: A and B as 
in legend to fig.1. Flow rate: 1 ml/min. Gradient: 
O-40% B, 40 min, indicated by the dotted line. 
Gly2, Glxi, Leur, Lysi, Valr, suggesting the se- 
quence Gln-Gly-Leu-Val-Gly-Lys-Arg. Conse- 
quently, the findings suggested that the isolated 
peptide consisted of secretin extended C-terminally 
with Gly-Lys-Arg. If so, free arginine should be 
split from it on tryptic degradation and this was 
also shown to be the case. A tryptic digest was 
derivatized with PITC [13] and applied to an 
HPLC system for the detection of PTC-amino 
acids. All 5 tryptic peptide derivatives and free 
PTC-arginine were indeed detected. 
Taken together, the above data show that the 
isolated polypeptide really is a variant form of 
secretin with a C-terminal extension by Gly-Lys- 
Arg. This is in good agreement with the knowledge 
that a glycine residue followed by paired basic 
residues usually represents amidation and cleavage 
signals in peptide hormone precursors. It may be 
mentioned that the precursors of 3 other members 
of the secretin family, VIP, PHI and glucagon, 
also have the double basic amino acid combination 
Lys-Arg following the glycine residue involved in 
the amidation [16,17]. However, in a fourth 
member, somatocrinin (GRF), the glycine residue 
precedes a single basic residue, arginine [18]. 
Fig.4. Separation of the tryptic fragments of secretin 
(10 pg trypsin-degraded secretin) by reverse-phase 
HPLC using the same conditions as described in legend 
to fig.3. 
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Table 3 
Amino acid compositions of the tryptic fragments and the C-terminal chymotryptic fragment of the secretin variant 
Amino acid Tr 7-2 T3 T4 T5 Chymotryptic 
fragment 
LYS 
His 
Arg 
Asx 
Thr 
Ser 
GlX 
GlY 
Ala 
Val 
Leu 
Phe 
- - - - 1.0 (-) 0.9 (7) 
0.8 (1) - - - - - 
0.8 (1) 0.9 (1) 0.8 (1) 0.8 (1) - 0.9 (-) 
1.3 (1) - 1.3 (1) - - - 
2.0 (2) - - - - - 
2.8 (3) - 0.9 (1) - - - 
1.4 (1) - - 1.2 (1) 1.2 (1) 1.2 (1) 
1.0 (1) - - 1.5 (1) 2.0 (1) 
- - 1.0 (1) - - - 
- - - 1.3 (1) 0.9 (1) 
1.0 (1) 1.1 (1) 1.0 (1) 3.0 (3) 1.1 (1) 
0.9 (1) - - - _ 
12 2 4 3 6 4 
Values are molar ratios without correction for destruction, incomplete hydrolysis or impurity. Figures within 
parentheses are the numbers of amino acids in the corresponding secretin fragment 
The pure secretin variant was tested for bioac- 
tivity in the secretin bioassay described above. As 
shown in fig.5, secretin-Gly-Lys-Arg is more po- 
tent than secretin itself. It has been observed [8] 
that secretin-Gly is active in the secretin bioassay 
but the activity has never been quantitated. It is in- 
teresting to note that two immediate proforms to 
secretin, secretin-Gly and secretin-Gly-Lys-Arg, 
have now been isolated and found to be biological- 
ly active. It is important to stress that in both these 
studies the secretin variants were isolated from side 
fractions during secretin purification and that it 
cannot be excluded that some other fraction(s) 
around the starting materials may also contain 
these and possibly other variant forms. Therefore, 
it is impossible at this stage to know if the C- 
terminally extended forms of secretin are just 
short-lived precursors to the amidated secretin or if 
they exist in such amounts that their physiological 
activity is of importance. 
The biological activity of secretin-Gly-Lys-Arg 
is also worth noting from another point of view. In 
attempts to produce peptide hormones by hybrid 
DNA techniques, it has always been a problem to 
modify the C-terminal amino acid to the amidated 
form. Since the C-terminal amidation does not 
seem to be a requisite for bioactivity in the case of 
secretin, one can produce the natural occurring 
proform to secretin, secretin-Gly-Lys-Arg. A 
secretin analog terminating in a valine instead of a 
Fig.5. Dose-response curves for secretin and secretin- 
Gly-Lys-Arg. The assay was the bioassay for secretin 
described in section 2. (x) Secretin, (0) secretin-Gly- 
Lys-Arg. 
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valine amide residue has already been produced by 
such methodology [ 191. 
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